FULC

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for genetically defined diseases with high unmet medical needs. The company's proprietary FulcrumSeek product engine identifies drug targets that can modulate gene expression to treat the underlying cause of disease. Fulcrum's lead product candidates target serious rare diseases including facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease. The company employs precision medicine approaches to develop small molecule therapies that address specific genetic abnormalities. Founded in 2016 and headquartered in Cambridge, Massachusetts, Fulcrum is advancing multiple programs through clinical development with the goal of delivering transformative treatments for patients with rare genetic diseases.